PREVIOUS ISSUE NEXT ISSUE
December 2016 drtp1216_CV_Final_web.jpg
Key cogs in the management of Parkinson’s diseaseThe goal of this activity is to assist pharmacists in managing difficult-to-treat symptoms of Parkinson’s disease.
The year's Top DrugsSpecialty medications dominate
Remember When: The $4 generics battle was in full swingBelow-cost reimbursements still a concern for pharmacists.
How to Safeguard Against Fraudulent PrescriptionsRed flags—and what to do when your suspicions are aroused
Dispensed as written: Fingerprints
Pharmacies: The First Line of Defense Against the FluPharmacists guide and counsel patients about flu prevention and treatment.
Pharmacies Play a Key Role in One Business’ Mission to Help the Uninsured
Grant Helps Quantify the Value Pharmacists Can Have in Patient CareA recent grant from the Community Pharmacy Foundation, allowed Randy McDonough and his team to study the impact continuous medication monitoring has had on the pharmacy.
Pharmacists improve adherence in HIV careThe HIV-specialized pharmacy model can improve adherence and outcomes for patients.
Independent Pharmacies Tout Enhanced ServicesIndependent community pharmacies have a new tool to help them promote the enhanced services that they provide their patients.
Hospitals turn to RFID for medication replenishmentRFID technology in hospitals is far from ubiquitous. However, more and more facilities are adopting RFID technology in a variety of areas.
New combo therapy for chronic heart failureEntresto® is a newly approved combination of sacubitril, a neprilysin inhibitor, and valsartan, an angiotensin II receptor blocker (ARB) for patients who have chronic heart failure NYHA Class II-IV and reduced ejection fraction.
Spotlight on five new drugsSoliqua for Type 2 Diabetes, Intrarosa for dyspareunia, Lartruvo for soft tissue sarcoma, Zinplava for Clostridium difficile infection, Carnexiv (antiepileptic agent)
FDA approves lixisenatide for type 2 diabetesNew drug review
EpiPen Maker Strikes Deal with DOJIn October 2016 Mylan N.V. announced that its subsidiary, Mylan Inc., agreed to pay a $465 million settlement to the U.S. Department of Justice (DOJ) to resolve questions surrounding the classification of EpiPen Auto-Injector and EpiPen Jr Auto-Injector (EpiPen) for the Medicaid Drug Rebate Program.
Incidental Use and Disclosure of HIPAA InformationWhen a pharmacy learns of a HIPAA breach, it, and its business associates involved in the breach, are required to report the incident to the government. But not all violations are reportable and may not be considered a breach.
PREVIOUS ISSUE NEXT ISSUE